Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AT1001-020
Previous Study | Return to List | Next Study

Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03500094
Recruitment Status : Completed
First Posted : April 17, 2018
Results First Posted : November 30, 2021
Last Update Posted : November 30, 2021
Sponsor:
Information provided by (Responsible Party):
Amicus Therapeutics

Brief Summary:
This was an open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric participants 12 to <18 years of age with Fabry disease and amenable gene encoding α-galactosidase A (GLA) variants.

Condition or disease Intervention/treatment Phase
Fabry Disease Drug: Migalastat HCl 150 mg Phase 3

Expanded Access : An investigational treatment associated with this study has been approved for sale to the public.   More info ...

Detailed Description:

This was a Phase 3b, 2-stage, open-label, uncontrolled, multicenter study to evaluate the safety, PK, PD, and efficacy of migalastat treatment in pediatric participants 12 to <18 years of age and weighing ≥ 45 kilograms (99 pounds) with Fabry disease and amenable GLA variants. Participants must have been naïve to enzyme replacement therapy (ERT) or have stopped ERT at least 14 days at the time of screening.

Stage 1 was a treatment period of approximately 1 month (4 weeks); Stage 2 was a treatment period of 11 months and a 30-day (untreated) safety follow-up period. There was no break in treatment between Stages 1 and 2. Prior to Stage 1, there was a screening period lasting at least 14 days and up to 30 days (or more, if GLA genotyping was required). Stages 1 and 2 together consisted of a 12-month treatment period, and a 30-day safety follow-up period, for a total of approximately 13 months. Upon study completion, participants had the option to enroll in a long-term extension study conducted under a separate protocol (NCT04049760).

Participants were randomly assigned 1:1:1 to 1 of 3 PK sampling groups using interactive response technology (IRT). Four blood samples for the determination of migalastat concentrations in plasma were collected during Stage 1 study drug administration, and 1 PK (trough) sample was collected at Month 6 and again at Month 12.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 12 to <18 Years) With Fabry Disease and Amenable GLA Variants
Actual Study Start Date : September 27, 2018
Actual Primary Completion Date : February 2, 2021
Actual Study Completion Date : February 6, 2021


Arm Intervention/treatment
Experimental: migalastat HCl 150 mg
One migalastat 123 milligrams (mg) capsule equivalent to 150 mg migalastat hydrochloride (HCl) (herein referred to as "migalastat") was administered every other day for 12 months.
Drug: Migalastat HCl 150 mg
migalastat HCl 150 mg capsule
Other Names:
  • AT1001
  • Galafold




Primary Outcome Measures :
  1. Number Of Participants Who Experienced Treatment-related Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Day 1 (after dosing) through Month 12 and follow-up (30 days after last dose) ]
    TEAEs included adverse events that began on or after the first dose of study drug until 30 days after the last dose. Treatment-related TEAEs were defined as TEAEs that had an investigator-defined relationship to study drug of "Definite," "Probable," or "Possible." A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

  2. Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve Over The Dosing Interval (AUCtau) Of Migalastat [ Time Frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12 ]

    PK sampling was performed on 1 occasion at steady-state during the first month of the study. Adolescent participants were randomized to 3 sparse PK sampling groups based on optimal sampling theory. Each blood sample could have been taken at any time within the following time point ranges. Time point ranges for all 3 sparse sampling groups are arranged here in chronological order: 1 to 1.25 hours (h), 1.5 to 2h, 2.75 to 3.25h, 3.25 to 3.75h, 3.75 to 4.25h, 5 to 5.5h, 5.25 to 5.75h, 6.5 to 7h, 8.25 to 8.75h, 8.75 to 9.25h, and 10.75 to 11.25h post-dose. The combined sampling scheme resulted in rich data over an approximate 12-hour time course for AUC estimation. Additional trough samples were taken at Months 6 and 12. These trough samples (48h) assisted in estimating the terminal elimination phase for the AUC.

    Simulations were conducted to predict steady-state PK profiles and parameters for adolescent age subgroups 12 to <16 years, 16 to <18 years, and overall, 12 to <18 years.


  3. PK: Maximum Observed Plasma Concentration (Cmax) Of Migalastat [ Time Frame: 0 to 12 hours postdose during the first month of study and trough samples at Months 6 and 12 ]

    PK sampling was performed on 1 occasion at steady-state during the first month of the study. Adolescent participants were randomized to 3 sparse PK sampling groups based on optimal sampling theory. Each blood sample could have been taken at any time within the following time point ranges. Time point ranges for all 3 sparse sampling groups are arranged here in chronological order: 1 to 1.25h, 1.5 to 2h, 2.75 to 3.25h, 3.25 to 3.75h, 3.75 to 4.25h, 5 to 5.5h, 5.25 to 5.75h, 6.5 to 7h, 8.25 to 8.75h, 8.75 to 9.25h, and 10.75 to 11.25h post-dose. The combined sampling scheme resulted in rich data over an approximate 12-hour time course for AUC and Cmax estimation. Additional trough samples were taken at Months 6 and 12. These trough samples (48h) assisted in estimating the terminal elimination phase for the AUC.

    Simulations were conducted to predict steady-state PK profiles and parameters for adolescent age subgroups 12 to <16 years, 16 to <18 years, and overall, 12 to <18 years.



Secondary Outcome Measures :
  1. Change In eGFR From Baseline To Month 12 [ Time Frame: Baseline, Month 12 and last observation (up to Month 12) ]
    eGFR was calculated using the modified Schwartz formula for creatinine clearance.

  2. Annualized Rate Of Change From Baseline [ Time Frame: Baseline up to Month 12 ]
    Annualized rate of change from baseline of eGFR was defined as change from baseline to last visit divided by the duration from baseline to the last visit (Last assessment date - First dose date +1) and multiplied by 365.25. Baseline was defined as the last non-missing assessment prior to the first dose of study drug.

  3. Change From Baseline In Total Urine Protein And Urine Albumin Levels At Month 12 [ Time Frame: Baseline, Month 12 and last observation (up to Month 12) ]
    Renal function was assessed by urine protein and urine albumin levels. Urine samples were collected as part of urinalysis to measure protein and albumin levels.

  4. Change From Baseline In Left Ventricular Mass Index (LVMi) [ Time Frame: Baseline, Month 12 and last observation (up to Month 12) ]
    LVMi was assessed as a measure of cardiac impairment in the study participants. LVMi values for both M Mode and 2D views are presented.

  5. Change In Plasma Levels Of Globotriaosylsphingosine (Lyso-Gb3) [ Time Frame: Baseline, Month 12 and last observation (up to Month 12) ]
    Blood samples were collected for measurement of lyso-Gb3 levels in plasma. Plasma levels of lyso-Gb3 were measured using a validated liquid chromatography-mass spectrometry assay.

  6. FABPRO-GI And Pain Scores [ Time Frame: Month 12 and last observation (up to Month 12) ]
    The Fabry Disease Patient-Reported Outcome - Gastrointestinal Signs And Symptoms (FABPRO-GI) And Pain Questionnaire For Clinical Trials (24-hr Version) consists of questions regarding gastrointestinal signs and symptoms and pain relative to the past 24 hours. Participants rated the severity of their symptoms and pain from 0 (none) to 10 (worst possible). The monthly average score at Month 12 and at last observation are presented. A higher score indicated higher levels of symptoms and pain.

  7. Patient's Global Impression Of Change (PGI-C) Scores [ Time Frame: Month 12 ]
    The PGI-C consists of 4 questions regarding diarrhea, abdominal pain, overall pain, and daily living. Participants rated their status based on improvement, worsening, or the same. Improved status includes "Much better", "Better" and "A little better"; worsened status includes "A little worse", "Worse" and "Much worse".

  8. Number Of Participants Who Experienced Sudden Onset Of Pain As Assessed Using The Fabry-Specific Pediatric Health And Pain Questionnaire (FPHPQ) [ Time Frame: Month 12 ]
    The assessment of "In the last 3 months how many times did you experience sudden onset of pain?" using the FPHPQ for ages 13 to 18 is presented.

  9. Change From Baseline In FPHPQ Score For Pain Intensity [ Time Frame: Baseline, Month 12 and last observation (up to Month 12) ]
    The assessment of "How bad is your pain today?" using the FPHPQ for ages 13 to 18 is presented. Pain intensity was measured on a 10-point scale, 0 (no pain) to 10 (pain as bad as you can imagine). A decrease from baseline indicates an improvement in the condition.

  10. Change From Baseline In Pediatric Quality Of Life (PedsQL) At Month 12 [ Time Frame: Baseline, Month 12 ]

    The PedsQL is a modular approach to measuring health-related quality of life in healthy children and adolescents and those with acute and chronic health conditions. The psychosocial score for the PedsQL encompassed 15 questions relating to the participants' feelings, social interaction with others, and school. The physical score was derived from answers to 8 questions about the participants' ease of managing physical activity.

    All components of the PedsQL were scored based on a scale of 0 (never) to 4 (almost always) and linearly transformed to a 0-100 scale as follows: 0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0. Both categories were combined for a total score. Total scores for the child report ages 13 to 18 years old and parent report are presented at Month 12.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria

  • Willing and able to provide written consent or assent (participant and parent/legal guardian, as applicable)
  • Male or female between 12 and <18 years of age diagnosed with Fabry disease
  • Confirmed, amenable GLA variant
  • Participant weighed at least 45 kg (99 pounds) at screening
  • Participant had never been treated with ERT or had not received ERT for 14 days prior to screening
  • Participant had at least 1 complication (such as, laboratory abnormality and/or sign/symptom) of Fabry disease
  • Participant was able to swallow study medication whole

Key Exclusion Criteria

  • Had moderate or severe renal impairment (estimated glomerular filtration rate (eGFR) <60 milliliter/minute/1.73 meter squared (m^2) at screening)
  • Had advanced kidney disease requiring dialysis or kidney transplantation
  • History of allergy or sensitivity to study medication (including excipients) or other iminosugars (for example, miglustat, miglitol)
  • Had received any gene therapy at any time or anticipated starting gene therapy during the study period
  • Required treatment with Glyset (miglitol) and/or Zavesca (miglustat) within 6 months before screening or throughout the study
  • Required treatment with Replagal (agalsidase alfa), or Fabrazyme (agalsidase beta) within 14 days before screening or throughout the study
  • Participant was treated or had been treated with any investigational/experimental drug, biologic or device within 30 days before screening
  • Any intercurrent illness or condition or concomitant medication use considered to be a contraindication at screening or baseline or that may have precluded the participant from fulfilling the protocol requirements or suggested to the investigator that the potential participant may have had an unacceptable risk by participating in this study
  • Pregnant or breast-feeding or planned to become pregnant during the study period
  • Otherwise unsuitable for the study in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03500094


Locations
Layout table for location information
United States, Florida
Clinical Study Site
Tampa, Florida, United States, 33606
United States, Georgia
Clinical Study Site
Atlanta, Georgia, United States, 30322
United States, Minnesota
Clinical Study Site
Minneapolis, Minnesota, United States, 55454
United States, Missouri
Clinical Study Site
Columbia, Missouri, United States, 65212
United States, Ohio
Clinical Study Site
Cincinnati, Ohio, United States, 45229
United States, Pennsylvania
Clinical Study Site
Pittsburgh, Pennsylvania, United States, 15224
United States, Virginia
Clinical Study Site
Fairfax, Virginia, United States, 22030
United Kingdom
Clinical Study Site
London, United Kingdom, NW3 2QG
Sponsors and Collaborators
Amicus Therapeutics
Investigators
Layout table for investigator information
Study Director: Medical Monitor Clinical Research Amicus Therapeutics
  Study Documents (Full-Text)

Documents provided by Amicus Therapeutics:
Study Protocol  [PDF] June 13, 2019
Statistical Analysis Plan  [PDF] October 20, 2020

Layout table for additonal information
Responsible Party: Amicus Therapeutics
ClinicalTrials.gov Identifier: NCT03500094    
Other Study ID Numbers: AT1001-020
2017-000146-21 ( EudraCT Number )
First Posted: April 17, 2018    Key Record Dates
Results First Posted: November 30, 2021
Last Update Posted: November 30, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Amicus Therapeutics:
Lysosomal storage disease
migalastat
AT1001
Galafold
Additional relevant MeSH terms:
Layout table for MeSH terms
Fabry Disease
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders